Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. by Nacul, Luis C et al.
Patel, H; Bell, D; Molokhia, M; Srishanmuganathan, J; Patel, M; Car,
J; Majeed, A (2007) Trends in hospital admissions for adverse drug
reactions in England: analysis of national hospital episode statistics
1998-2005. BMC Clin Pharmacol, 7. p. 9. ISSN 1472-6904
Downloaded from: http://researchonline.lshtm.ac.uk/7790/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
Page 1 of 11
(page number not for citation purposes)
Research article
Trends in hospital admissions for adverse drug reactions in England: 
analysis of national hospital episode statistics 1998–2005
Hitesh Patel*1, Derek Bell2, Mariam Molokhia3, 
Janakan Srishanmuganathan4, Mitesh Patel1, Josip Car5 and Azeem Majeed5
Address: 1Charing Cross Hospital, London W6 8RF, UK, 2Chelsea and Westminster Hospital, London SW10 9NH, UK, 3Department of 
Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, WC1E 7HT, UK, 4St Mary's Hospital, London W2 1NY, 
UK and 5Department of Primary Care and Social Medicine, Imperial College, London W6 8RF, UK
Email: Hitesh Patel* - dochiteshpatel@hotmail.com; Derek Bell - d.bell@imperial.ac.uk; Mariam Molokhia - mariam.molokhia@lshtm.ac.uk; 
Janakan Srishanmuganathan - sjanakan@hotmail.com; Mitesh Patel - mitesh.patel@doctors.net; Josip Car - josip.car@imperial.ac.uk; 
Azeem Majeed - a.majeed@imperial.ac.uk
* Corresponding author    
Abstract
Background: Adverse drug reactions (ADRs) are a frequent cause of mortality and morbidity to
patients worldwide, with great associated costs to the healthcare providers including the NHS in
England. We examined trends in hospital admissions associated with adverse drug reaction in
English hospitals and the accuracy of national reporting.
Methods: Data from the Hospital Episode Statistics database (collected by the Department of
Health) was obtained and analysed for all English hospital episodes (1998–2005) using ICD-10
codes with a primary (codes including the words ('drug-induced' or 'due to') or secondary diagnosis
of ADR (Y40–59). More detailed analysis was performed for the year 2004–2005
Results: Between 1998 and 2005 there were 447 071 ADRs representing 0.50% of total hospital
episodes and over this period the number of ADRs increased by 45%. All ADRs with an external
code increased over this period. In 2005 the total number of episodes (all age groups) was
13,706,765 of which 76,692 (0.56%) were drug related. Systemic agents, which include anti-
neoplastic drugs, were the most implicated class (15.7%), followed by analgesics (11.7%) and
cardiovascular drugs (10.1%). There has been a 6 fold increase in nephropathy secondary to drugs
and a 65% decline in drug induced extra-pyramidal side effects. 59% of cases involving adverse drug
reactions involved patients above 60 years of age.
Conclusion: ADRs have major public health and economic implications. Our data suggest that
national Hospital Episode Statistics in England have recognised limitations and that consequently,
admissions associated with adverse drug reactions continue to be under-recorded. External causes
of ADR have increased at a greater rate than the increase in total hospital admissions. Improved
and more detailed reporting combined with educational interventions to improve the recording of
ADRs are needed to accurately monitor the morbidity caused by ADRs and to meaningfully
evaluate national initiatives to reduce adverse drug reactions.
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Background
Adverse drug reactions cause considerable morbidity and
mortality world-wide [1] and in many cases are avoidable.
Pirmohamed and colleagues estimated that in England,
adverse drug reactions were responsible for around 6.5%
of all acute hospital admissions and at least 5,000 deaths
per year [2]. In the USA, adverse drug reactions are one of
the leading causes of death in the population [3]. Hence,
adverse drug reactions have a major impact on public
health, reducing patients' quality of life and imposing a
considerable financial burden on the health care systems
at a time when many health care systems are under con-
siderable financial strain.
Drug reactions can be typically described in two groups.
Type A reactions "intrinsic" (which are often dose-
dependent) are relatively common. Type B reactions are
usually more serious: idiosyncratic reactions that are not
necessarily dose-dependent. We expect the majority of
ADR admissions to be Type A reactions. Notification to
pharmacovigilance agencies (e.g. the Medicines and
Healthcare products Regulatory Agency yellow card in the
UK) is designed to capture new ADRs not known at the
marketing stage, i.e. usually but not exclusively, Type B
reactions.
Adverse drug reactions are commonest amongst the eld-
erly [2] This is not surprising as the elderly generally have
the highest prevalence of long-term diseases [4]. Poly-
pharmacotherapy, combined with a poorer physiological
reserve, puts the elderly particularly at risk of adverse drug
reactions [5]. Poly-pharmacotherapy amongst elderly
patients is likely to increase still further through the
implementation of 'pay for performance' schemes, such as
the new contract for NHS general practitioners in the UK.
This rewards tighter meeting of 'treatment targets' for spe-
cific long-term diseases, such as high blood pressure or
high cholesterol, which commonly results in prescribing
of higher doses of medication or poly-pharmacotherapy
with higher number of different medications than in the
past.
More evidence-based prescribing for long-term diseases
will benefit patients, but may also increase the number of
adverse drug reactions in the population merely because
of the potential for increased drug reactions. The number
of older people in the population of developed countries
is also increasing rapidly. For example, in the United King-
dom, the number of people aged 65 years and over is pre-
dicted to increase by around 53% between 2001 and 2031
[6]. This increase in the elderly population combined with
increased prescribing for long-term diseases is likely to
result in an increase in the number of people at risk of suf-
fering from adverse drug reactions.
Despite the importance of adverse drug reactions, meth-
ods for monitoring them are limited. Some adverse drug
reactions are identified during clinical trials during drug
development and testing, however, rare reactions may fail
to be detected. Once a drug is marketed, detection of
adverse drug reactions generally depends on notifications
to regulatory authorities, such as the Medicines and
Healthcare products Regulatory Agency, which runs the
yellow card scheme in the United Kingdom. However,
even for serious and well-recognized ADRs notification of
adverse drug reactions from such spontaneous reporting
schemes is low, often less than 10% and even lower where
the association between the drug and the adverse event is
unknown [7].
Hence, many adverse drug reactions do not become
apparent until a drug has been in widespread use for sev-
eral years. Consequently, current systems for the detection
of ADRs have serious limitations. For example, the associ-
ations between COX-2 inhibitors and increased risk for
myocardial infarction and stroke were only highlighted
and reviewed after these drugs had been used for several
years by hundreds of thousands of patients, although ini-
tial concerns were identified from trial data [8].
Other information on adverse drug reactions comes from
ad-hoc studies. However, with a few exceptions, such as
the study by Pirmohamed and colleagues in North-West
England, [2] these previous studies have tended to be
small (although with similar results; often based in one
hospital) and many are now very old [1].
Hospital Episode Statistics (HES) are collected by the
Department of Health and contain details of all admis-
sions to NHS hospitals in England [9]. HES data includes
private patients treated in NHS hospitals, patients who
were resident outside of England and care delivered by
treatment centres (including those in the independent
sector) but funded by the NHS. HES were established in
1987 following a report on the collection and use of hos-
pital activity information published by a steering group
chaired by Dame Edith Körner [10]. Before 1987, only a
10 per cent sample of admitted patient records were col-
lected nationally whereas HES collect a detailed record for
each 'consultant episode' of admitted patient care deliv-
ered by NHS hospitals in England.
HES data are available for every financial year from 1989–
90 onwards but the dataset has been modified over time
to reflect changing administrative requirements and the
introduction of new clinical classifications. For example,
in 1995, the recording of diagnoses changed from the 9th
to the 10th revision of the International Classification of
Diseases (ICD) [9]. In the 2004–05 financial year, there
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were about 12.1 million hospital admissions, resulting in
nearly 14 million consultant episodes, in England.
Waller and colleagues [11], studied HES data from 1996–
2000, looking at 258, 222 episodes associated with con-
firmed ADRs and concluded that HES grossly underesti-
mates the burden of ADRs. As part of preparatory work for
projects on the epidemiology of adverse drug reactions,
and educational interventions to improve recording of
these reactions, we wished to examine the contribution of
recorded adverse drug reactions to acute hospital admis-
sions nationally. We aimed to examine the current epide-
miology of hospital admission for adverse drug reactions,
the age distribution of these admissions, and their impact
on hospital activity. We also aimed to compare estimates
of hospital admissions due to adverse drug reactions to
those from previous studies to determine how well
adverse drug reactions were being recorded in current
practice and how much scope there was to improve
recording.
Methods
We obtained for the period 1998–2005 from the Depart-
ment of Health, HES-records in which there was an ICD10
code containing the words 'drug-induced' or which indi-
cated that a diagnosis was 'due to' a drug. We also studied
codes in the range Y40 – Y59 ("correct drug properly
administered in therapeutic or prophylactic dosage as the
cause of any adverse effect"), otherwise known as 'external
cause' (Table 1). This excludes accidental or intentional
poisoning due to drugs. We studied codes that explicitly
stated that the episode was caused by a drug. Thus, we did
Table 1: ICD-10 codes (Y40–Y59) for drugs, medicaments and biological substances causing adverse effects in therapeutic use
ICD-10 External cause mortality/morbidity by:
Y40 Systemic antibiotics: Penicillins, cefalosporins and other beta-lactam antibiotics, chloramphenicol, macrolides, tetracyclines, 
aminoglycosides, rifamycins, antifungals, others
Y41 Other systemic anti-infectives and antiparasitics: Sulphonamides, other anti-mycobacterial, anti-malarials, anti-protozoal, anti-
helminthics, anti-virals
Y42 Hormones and substitutes: Glucocorticoids, thyroid hormones, anti-thyroids, insulin, oral hypoglycaemics, oral contraceptives, 
oestrogen and progestogen, anti-gonadotrophins, anti-oestrogens, anti-progestogens, androgens
Y43 Systemic agents: Anti-allergic and anti-emetic drugs, anti-neoplastic and immunosuppressive drugs, acidifying/alkalising agents
Y44 Agents affecting blood constituents: Iron preparations, anti-megaloblastic-anaemia preparations, anticoagulants, anticoagulant 
antagonists, antithrombotic drugs, thrombolytic drugs, blood products, plasma substitutes
Y45 Analgesics, anti-pyretics and anti-inflammatory drugs: Opioids and related analgesics, salicylates, propionic acid derivatives, 
nonsteroidal anti-inflammatory drugs, antirheumatics, 4-aminophenol derivatives
Y46 Anti-epileptics and anti-parkinsonism drugs: Succinimides, oxazolidinediones, hydantoin derivatives, deoxybarbiturates, 
iminostilbenes, valproic acid, anti-parkinsonism drugs, anti-spasticity drugs
Y47 Sedatives, hypnotics and anti-anxiety drugs: Barbiturates, benzodiazepines, cloral derivatives, paraldehyde, bromine 
compounds, sedative, hypnotic and antianxiety drug, unspecified
Y48 Anaesthetics and therapeutic gases: Inhaled/parenteral anaesthetics, local anaesthetics, therapeutic gases
Y49 Psychotropic drugs: Tricyclic and tetracyclic antidepressants, monoamine-oxidase-inhibitor, phenothiazine antipsychotics and 
neuroleptics, butyrophenone and thioxanthene neuroleptics, other antidepressants, antipsychotics and neuroleptics
Y50 Central nervous system stimulants: Analeptics, opioid receptor antagonists, methylxanthines, other central nervous system 
stimulants
Y51 Drugs primarily affecting the autonomic nervous system: Anticholinesterase agents, cholinergics, ganglionic blocking drugs, 
anticholinergics, antimuscarinics, spasmolytics, alpha-adrenoreceptor agonists/antagonists, beta-adrenoreceptor agonists/antagonists, 
centrally acting and adrenergic-neuron-blocking agents
Y52 Agents affecting the cardiovascular system: Cardiac-stimulant glycosides, calcium-channel blockers, other anti-dysrhythmic 
drugs, other coronary vasodilators, angiotensin-converting-enzyme inhibitors, other anti-hypertensives, anti-hyperlipidaemic and anti-
arteriosclerotic drugs, peripheral vasodilators, anti-varicose drugs
Y53 Agents affecting the gastrointestinal system: Antacids, anti-gastric-secretion drugs, laxatives, anti-diarrhoeal, emetics
Y54 Agents affecting water-balance and mineral and uric acid metabolism: Mineralocorticoids, mineralocorticoid antagonists, 
carbonic-anhydrase inhibitors, benzothiadiazine derivatives, other diuretics, electrolytic, caloric and water-balance agents, agents 
affecting calcification, agents affecting uric acid metabolism
Y55 Agents acting on smooth and skeletal muscles and the respiratory system: Oxytocic drugs, skeletal muscle relaxants, anti-
tussives, expectorants, anti-common-cold drugs, anti-asthmatics
Y56 Topical agents primarily affecting skin and mucous membrane: Local anti-fungal, anti-infective, anti-inflammatory drugs, anti-
pruritics, local detergents, emollients, keratolytics, ophthalmological drugs, otorhinolaryngological drugs, dental drugs
Y57 Other and unspecified drugs: Appetite depressants, lipotropic drugs, antidotes and chelating agents, alcohol deterrents, x-ray 
contrast media, vitamins
Y58 Bacterial vaccines
Y59 Other vaccines: Viral/rickettsial/protozoal vaccines, immunoglobulin
Includes: Correct drug properly administered in therapeutic or prophylactic dosage as the cause of any adverse effect Excludes: Accidental 
overdose of drug or wrong drug given or taken in error (X40–X44); accidents in the technique of administration of drugs, medicaments and 
biological substances in medical and surgical procedures (Y60–Y69)
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not include conditions like toxic epidermal necrolysis,
which is invariably drug induced but does have other
known causes.
HES records contain a main diagnosis field and up to 13
secondary diagnosis fields (seven before 2002/3). We
examined the number of episodes per year and for the
most recent year for which data was available (2004/05);
we also examined several other measures, including the
number of admissions by age and the total bed days used
by patients with diagnoses of adverse drug reactions. An
episode is defined as the time a patient spends under the
care of one consultant. Most admissions result in just one
episode of care and hence episodes are a reasonably good
proxy for admissions.
HES data is collected in financial year from 1 April to 31
March the following year. Our data is presented in this
format. HES data is collected comprehensively and under-
goes extensive processing and validation to maintain
quality. This process is detailed on their official website
[9]. Some of the data presented changed classification
during the time period and it became dubious whether
the episode was related exclusively to an ADR. These data
were not included and are marked as U/C (unclassified) in
the tables.
Results
Overall burden of hospital admissions for ADRs
Table 2 summarises the total number of episodes and the
total number of episodes associated with ADRs. In our
seven year study period, there were 88,822,005 total hos-
pital episodes and 447,041 episodes with a diagnostic
code indicative of ADRs (0.5%). Of these 68,971 (0.08%)
were primary diagnoses and 378,070 (0.4%) were of
'external cause'.
Change in burden
Between 1998–2005, the total number of hospital epi-
sodes increased by 14% but the total number of reported
episodes linked with ADRs increased by 45% (largely due
to an increase in external cause codes). Table 3 and 4 high-
light the burden of ADRs according to ICD-10 code. Drug
induced haemolytic anaemia (927%), nephropathy
(590%), adrenocortical failure (146%), cardiomyopathy
(144%) and aplastic anaemia (139%) were the five fastest
growing ADRs as a primary diagnosis (Table 3). In con-
trast, the top five fastest growing ADRs as external causes
were drugs relating to: water balance (164%), autonomic
system (108%), central nervous system stimulants
(102%), cardiovascular system (92%) and biologicals/
vaccines (77%). Primary diagnosis of ADRs decreased by
1% during this study. Reported rates under the categories
of 'drug-induced extra-pyramidal side effects' (-65%) and
'malignant hyperpyrexia' (-33%) showed the largest
declines (Table 3).
Detailed overview for 2004–5
In 2004, there were 10,396 (0.08%) ADR admissions
associated with a primary diagnosis and 66,296 (0.5%)
ADRs as a secondary cause. Combined, they account for
0.56% of hospital episodes. The three commonest classes
of adverse drug reaction, classified as an external cause
(Table 4) resulting in hospital admission were systemic
agents (Y43); analgesics, antipyretics and anti-inflamma-
tory drugs (Y45); and systemic antibiotics (Y40). 'Mental
disorders' secondary to opioids and psychoactive drugs
reflected 63% of all the primary diagnoses of ADR (Table
3).
Most hospital episodes associated with adverse drug reac-
tions occurred in the elderly. In 2004–5, 59% of hospital
episodes in which there was an external ICD10 code for
an adverse drug reaction occurred in people aged 60 years
and over. The mean age of ADRs was 60 (Table 5, 6).
Younger patients tended to have ADRs from vaccines and
psychoactive drugs.
The majority of adverse drug reactions were reported in
females (58%). By contrast, females accounted for 51% of
all hospital admissions in 2004–05. Men were more likely
to suffer from mental disorders due to psychoactive drugs
and women were more likely to suffer from drug induced
nephropathy and systemic lupus erythematosus. On aver-
age, each episode associated with an adverse drug reaction
required a hospital admission lasting 9.7 days (compared
with 7.1 days as the mean length of stay for admissions
due to any cause). Episodes with a record of an adverse
drug reaction accounted for 0.8% (439,685/54,554,697)
of total bed days in 2004–05.
Table 2: Total number of Hospital Episode Statsitics for which there was a primary diagnosis or 'external cause' of ADR 1998–2005
1998–9 1999–00 2000–1 2001–2 2002–3 2003–4 2004–5 % Change 
1998–2005
Total No. of Episodes 11,983,893 12,167,574 12,674,277 12,357,360 12,757,656 13,174,480 13,706,765 14.4
No. with 'drug induced' codes 10506 10105 9823 9442 9246 9453 10396 -1.0
No. with external cause codes 42,555 47,385 50,113 52,160 56,943 62,618 66,296 55.8
Total Adverse Drug Reactions 53,061 57,490 59,936 61,602 66,189 72,071 76,692 44.5
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Table 3: Annual number of Hospital Episode Statistics finished consultant episodes with a primary diagnosis for an ADR (ICD-10 code)
ICD-10 1998–9 1999–00 2000–1 2001–2 2002–3 2003–4 2004–5 % Change 1998–2005
D59.0/2 Drug induced haemolytic anaemia 15 30 28 37 34 36 154 926.7
D61.1 Drug induced aplastic anaemia 101 116 114 186 182 162 241 138.6
E03.2 Hypothyroidism due to medicaments 23 23 12 12 19 13 26 13.0
E27.3 Drug induced adrenocortical failure 24 22 24 38 39 53 59 145.8
F11 Mental disorders due to opioids 4360 4287 4398 4187 3916 3690 3746 -14.1
F13 Mental disorders due to sedatives/hypnotics 223 247 247 239 232 206 189 -15.2
F19 Mental disorders due to multiple psychoactive drugs 3513 3137 2725 2643 2601 2690 2775 -21.0
G21.0 Malignant neuroleptic syndrome 101 106 121 108 102 93 128 26.7
G21.1 Drug induced Parkinsonism 145 115 124 133 112 108 149 2.8
G24.0 Drug induced dystonia 149 130 145 130 115 152 109 -26.8
G25.1/4/6 Drug induced extrapyramidal syndrome/chorea/tics 136 146 110 125 44 51 48 -64.7
G72.0 Drug induced myopathy 47 53 51 51 57 39 55 17.0
H91.0 Ototoxic hearing loss 2 5 3 3 2 U/C1 U/C U/C
I42.7 Drug induced cardiomyopathy 25 25 53 38 67 77 61 144.0
J70.2/3/4 Drug induced interstitial lung disorders 54 45 43 43 86 71 94 74.1
K71 Drug induced liver disease 406 318 372 351 459 437 448 10.3
L56.0/1 Drug induced phototoxicity 4 5 2 4 1 3 5 25.0
M10.2 Drug induced gout 30 27 13 24 22 22 34 13.3
M32.0 Drug induced systemic lupus erythematosus 17 20 12 13 14 10 26 52.9
M34.2 Drug induced systemic sclerosis 3 3 4 3 U/C U/C U/C U/C
N14 Drug induced nephropathy 60 69 92 85 100 318 414 590.0
T88.3 Malignant hyperthermia due to anaesthesia 6 4 10 3 3 5 4 -33.3
T88.6 Drug induced anaphylaxis 366 435 399 384 375 469 563 53.8
T88.7 Unspecified adverse drug effect 696 737 721 602 664 748 1068 53.4
Total 10506 10105 9823 9442 9246 9453 10396 -1.0
1U/C – unclassified: data not available due to a coding change
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Table 4: Annual number of HES finished consultant episodes with an 'external code' for an adverse drug reaction
ICD-10 1998–9 1999–00 2000–1 2001–2 2002–3 2003–4 2004–5 % Change 
1998–2005
Y40 Systemic antibiotics 4,206 4,212 4,533 4,341 4,697 5,624 6,449 53.3
Y41 Other systemic anti-infectives/anti-parasitics 829 816 1,017 945 1,195 1,134 1,453 75.3
Y42 Hormones (including synthetic, antagonists) 4,547 5,088 4,934 5,113 5,803 5,461 5,319 17
Y43 Primarily systemic agents 7,501 8,271 9,078 9,877 10,766 11,226 12,054 60.7
Y44 Agents primarily affecting blood constituents 4,062 4,483 4,723 4,797 5,230 5,995 4,272 5.2
Y45 Analgesics/antipyretics/anti-inflammatory 5,951 6,726 6,787 6,819 7,540 8,079 9,004 51.3
Y46 Antiepileptics/antiParkinsonism drugs 1,230 1,267 1,224 1,340 1,401 1,501 1,628 32.4
Y47 Sedatives, hypnotics, anti-anxiety drugs 370 400 450 430 480 586 560 51.4
Y48 Anaesthetics, therapeutic gases 414 538 502 440 505 521 531 28.3
Y49 Psychotropic drugs 1,653 1,678 2,008 1,992 1,953 2,364 2,544 53.9
Y50 Central nervous system stimulants 46 67 75 76 69 71 93 102.2
Y51 Drugs affecting autonomic nervous system 1,702 2,056 2,277 2,470 2,686 3,239 3,532 107.5
Y52 Agents primarily affecting cardiovascular system 4,044 4,752 5,376 5,667 6,234 6,836 7,768 92.1
Y53 Agents primarily affecting gastrointestinal system 398 410 486 416 461 579 656 64.8
Y54 Agents affecting water/mineral balance/uric acid 2,136 2,617 2,945 3,526 4,151 5,118 5,638 164
Y55 Agents affecting muscle/respiratory system 312 299 342 321 323 430 422 35.3
Y56 Topical agents affecting skin/ENT, dental 1,138 1,236 983 1,202 1,065 1,079 1,224 7.6
Y57 Other and unspecified medicaments 1,524 1,715 1,780 1,907 1,906 2,014 2,398 57.3
Y58 Bacterial vaccines 226 347 255 182 197 356 281 24.3
Y59 Other vaccines/biologicals 266 407 338 299 281 405 470 76.7
Total 42,555 47,385 50,113 52,160 56,943 62,618 66,296 55.8
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Table 5: Number of HES finished consultant episodes with a primary diagnosis of an ADR in 2004/05: mean age of admissions, age & gender distribution of episodes and total 
bed days
ICD-10 Male % Mean age Age 0–14 (%) Age 15–59 (%) Age 60–74 (%) Age 75+ (%) Total Bed days
D59.0/2 Drug induced haemolytic anaemia 49 63 0 (0.0) 52 (0.5) 75 (0.8) 27 (0.3) 160
D61.1 Drug induced aplastic anaemia 49 64 2 (0.0) 89 (0.9) 74 (0.7) 73 (0.7) 604
E03.2 Hypothyroidism due to medicaments 42 72 0 (0.0) 6 (0.1) 3 (0.0) 17 (0.2) 191
E27.3 Drug induced adrenocortical failure 41 48 11 (0.1) 22 (0.2) 12 (0.1) 14 (0.1) 584
F11 Mental disorders due to opioids 66 32 14 (0.1) 3681 (36.9) 33 (0.3) 14 (0.1) 47390
F13 Mental disorders due to sedatives/hypnotics 54 47 6 (0.1) 123 (1.2) 33 (0.3) 27 (0.3) 4922
F19 Mental disorders due to multiple psychoactive drugs 75 31 14 (0.1) 2734 (27.4) 17 (0.2) 10 (0.1) 64152
G21.0 Malignant neuroleptic syndrome 67 50 0 (0.0) 88 (0.9) 28 (0.3) 12 (0.1) 2,315
G21.1 Drug induced Parkinsonism 43 77 1 0.0) 11 (0.1) 44 (0.4) 93 (0.9) 1,964
G24.0 Drug induced dystonia 47 43 10 (0.1) 65 (0.7) 16 (0.2) 18 (0.2) 550
G25.1/4/6 Drug induced extrapyramidal syndrome/chorea/tics 40 64 2 (0.0) 15 (0.2) 18 (0.2) 13 (0.1) 407
G72.0 Drug induced myopathy 51 65 1 (0.0) 12 (0.1) 20 (0.2) 22 (0.2) 517
H91.0 Ototoxic hearing loss U/C U/C U/C U/C U/C U/C U/C
I42.7 Drug induced cardiomyopathy 48 43 7 (0.1) 42 (0.4) 7 (0.1) 5 (0.1) 376
J70.2/3/4 Drug induced interstitial lung disorders 49 64 3 (0.0) 24 (0.2) 40 (0.4) 27 (0.3) 858
K71 Drug induced liver disease 43 47 12 (0.1) 315 (3.2) 50 (0.5) 71 (0.7) 3408
L56.0/1 Drug induced phototoxicity 0 47 1 (0.0) 2 (0.0) 2 (0.0) 0 (0.0) 17
M10.2 Drug induced gout 53 75 0 (0.0) 4 (0.0) 9 (0.1) 21 (0.2) 237
M32.0 Drug induced systemic lupus erythematosus 27 43 0 (0.0) 19 (0.2) 2 (0.0) 5 (0.1) 69
M34.2 Drug induced systemic sclerosis U/C U/C U/C U/C U/C U/C U/C
N14 Drug induced nephropathy 2 58 0 (0.0) 3 (0.0) 5 (0.1) 3 (0.0) 111
T88.3 Malignant hyperthermia due to anaesthesia 75 20 2 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 8
T88.6 Drug induced anaphylaxis 37 52 19 (0.2) 326 (3.3) 130 (1.3) 87 (0.9) 883
T88.7 Unspecified adverse drug effect 33 50 80 (0.8) 565 (5.7) 203 (2.0) 217 (2.2) 2,471
Total 33 40 185 (1.9) 8200 (82.1) 821 (8.2) 776 (7.8) 132194
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Table 6: Number of HES finished consultant episodes with an external ICD10 cause for an adverse drug reaction in 2004/05: mean age of admissions, age & gender 
distribution of episodes and total bed days
ICD-10 Male % Mean age Age 0–14 (%) Age 15–59 (%) Age 60–74 (%) Age 75+ (%) Total bed days
Y40 Antibiotics 40 57 467 (0.7) 2468 (3.7) 1433 (2.2) 2064 (3.1) 48,868
Y41 Other anti-infectives 39 55 48 (0.1) 776 (1.2) 245 (0.4) 362 (0.5) 9,280
Y42 Hormones 37 61 173 (0.3) 2051 (3.1) 1571 (2.4) 1513 (2.3) 31,323
Y43 Systemic agents 46 52 1475 (2.2) 5123 (7.7) 4107 (6.2) 1323 (2.0) 83,049
Y44 Blood constituents 47 70 37 (0.1) 830 (1.3) 1331 (2.0) 2072 (3.1) 31,919
Y45 Analgesics, antipyretics, anti-inflammatory 44 66 101 (0.2) 2756 (4.2) 2392 (3.6) 3746 (5.7) 50,118
Y46 Antiepileptics, antiparkinsonism 51 59 69 (0.1) 641 (1.0) 434 (0.7) 484 (0.7) 15,002
Y47 Sedatives, hypnotics, anti-anxiety 43 56 54 (0.1) 210 (0.3) 104 (0.2) 190 (0.3) 4,782
Y48 Anaesthetics, therapeutic gases 47 50 32 (0.0) 275 (0.4) 145 (0.2) 78 (0.1) 2,263
Y49 Psychotropic drugs 39 65 33 (0.0) 822 (1.2) 610 (0.9) 1076 (1.6) 25,733
Y50 Central nervous system stimulants 46 51 6 (0.0) 47 (0.1) 17 (0.0) 23 (0.0) 404
Y51 Autonomic nervous system 49 73 16 (0.0) 473 (0.7) 1037 (1.6) 2006 (3.0) 16,886
Y52 Cardiovascular system 47 75 15 (0.0) 870 (1.3) 2210 (3.3) 4669 (7.1) 48,189
Y53 Gastrointestinal system 39 62 30 (0.0) 222 (0.3) 163 (0.2) 239 (0.4) 3,597
Y54 Water-balance, mineral and uric acid 33 77 13 (0.0) 411 (0.6) 1360 (2.1) 3848 (5.8) 42,568
Y55 Smooth/skeletal muscle, respiratory system 39 56 24 (0.0) 182 (0.3) 105 (0.2) 111 (0.2) 2,232
Y56 Topical agents 42 58 68 (0.1) 459 (0.7) 344 (0.5) 351 (0.5) 5,779
Y57 Other unspecified drugs 43 60 87 (0.1) 894 (1.4) 649 (1.0) 760 (1.1) 15,835
Y58 Bacterial vaccines 52 10 243 (0.4) 15 (0.0) 14 (0.0) 9 (0.0) 296
Y59 Other vaccines, biological substance 51 28 211 (0.3) 162 (0.2) 57 (0.1) 40 (0.1) 1,562
Total 43 63 3202 (4.8) 19687 (29.7) 18328 (27.7) 24964 (37.7) 439,685
Combined Primary Diagnosis and External Cause 42 60 3387 (4.4) 27887 (36.6) 19149 (25.1) 25740 (33.8) 571,879
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Discussion
This national study on time trends for hospital admis-
sions for adverse drug reactions in England is unique in
covering such a large population and for such long time
period. Our data show that the number of admissions
linked to adverse drug reactions has increased substan-
tially over the time period covered by the study.
The reported increase of ADRs by 45% may be accounted
by improving record keeping due to increased awareness,
a general increase in ADRs against a background of an
increasingly elderly population, the introduction of new
drugs and poly-pharmacotherapy because of increased
pressure to prescribe medication for chronic diseases. For
example, Swedish studies have shown a substantial
increase over the last 30 years in the average number of
drugs prescribed to patients who were admitted to hospi-
tal because of an ADR [12,13]. Our data shows a continu-
ation of the trends in Waller's and colleague's paper,
which reported a 40% increase in ADRs between 1996–
2000. When interpreting any results, we must bear in
mind the limitations of this study, which are outlined
below. However, even in 2004/05, adverse drug reactions
accounted for only about 0.56% of all emergency hospital
episodes in that year. This is substantially less than the 5%
of emergency hospital admissions generally quoted from
other studies, suggesting there is considerable under-
recording of adverse drug reactions in routine hospital
activity data.
The strengths of our study over earlier work include its
longitudinal nature and its completeness in that it covers
all NHS hospital admissions in England. All submitted
HES data are verified, validated and where appropriate
overwritten to maintain accuracy. Furthermore, the data
are compared with the independent Körner aggregate
returns (KP 70) to ensure that all consultant episodes are
captured [14]. However, our data has the weaknesses asso-
ciated with routinely collected data, such as missing,
incomplete or inaccurate data. It is likely that the effects of
these would lead us to under-estimate the true burden of
ADRs on the NHS. HES data are also collected locally at
hospitals in a process that involves different coders and
clinicians, and this may introduce variability in coding
practice between hospitals. Consequently, there are errors
in HES data with, for example, up to 22% error rates in
codes reported in plastic surgery [15]. Despite this, HES
remain a key source of information on hospital activity in
England's NHS. We did not have access to mortality data
associated with our hospital episodes, which would have
given more insight into the severity of ADRs associated
with hospital admissions.
Potential sources of bias
We do not have data on the total number of each drug
group prescribed and hence we are unable to conclude
whether adverse drug reactions were more common with
certain drug groups because they are prescribed more
often or whether the drugs are more likely to lead to an
adverse event. The number of admissions is likely to
reflect a combination of these two factors. For example,
the increase in admissions due to agents affecting the car-
diovascular system (Y52) may reflect increased use of
these drugs to treat conditions such as hypertension or
heart failure in the general population.
The number of medications a patient takes is associated
with the risk of an adverse drug reaction, with the mean
rate increasing by 10% with each extra medication pre-
scribed [16]. HES data does not allow us to monitor the
effects of poly-pharmacotherapy on adverse drug reaction
trends directly. This could be done by using data from
computerised primary care records held by general practi-
tioners.
We did not have access to the raw data and thus were not
able to identify duplicates, which is another limitation of
HES data. However, the purpose of this study was to see
whether the freely available data (without further data
manipulations) from HES has a role in monitoring ADRs
and evaluating interventions to reduced ADRs.
Comparison with other studies
Overall trends
There are limited recent studies examining the epidemiol-
ogy of adverse drug reactions, especially in England [1].
Pirmohamed et al undertook a 6 month prospective study
of admissions to two North England hospitals. However,
even their study, which is widely cited and regarded as one
of the best sources of information on the epidemiology of
adverse drug reactions, reported on only 1225 admissions
linked to adverse drug reactions. Their estimate of that
6.5% of emergency admissions were associated with
adverse drug reactions may be an over-estimate because
they excluded groups such as children, women presenting
with obstetrics and gynaecological problems; both
women of child-bearing age and women are likely to have
relatively few admissions due to adverse drug reactions. A
recent two year survey of the National Electronic Surveil-
lance – All Injury Programme (NEISS-AIP) consisting of
63 US hospitals that are nationally representative, which
analysed over 21 000 emergency department visits due to
adverse drug reactions over two years, estimated they
accounted for 0.6% of all emergency department visits
[17].
Our estimates of ADRs from HES suggest an under-report-
ing in concordance with the conclusions of Waller and
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colleagues [11]. Our data showed a higher incidence of
ADRs than Waller's study, which is difficult to explain. It
may represent an increasing trend in ADRs, better record
keeping, or improved vigilance. The present study does
show emerging trends of drug induced nephropathy and
reduced incidence of side effects from Parkinson's disease.
We could theorise reasons for this but it would be difficult
to interpret without knowing the specific medicines caus-
ing these trends.
In the two most recent studies, length of stay in patients
with adverse drug reactions was 8 (median) [2]and 10.6
(mean) [3] days and is longer than current average hospi-
tal stays. Our study gives a similar mean value. The cost of
a hospital bed in the UK is €228 per day [18], however, it
is difficult to estimate the exact cost associated with hos-
pital episode related adverse drug reactions, given the
degree of underreporting. Shorter hospital stays may lead
to underreporting of adverse drug reactions.
Age
The elderly are known to experience more type A drug
reactions (predictable reactions related to the pharmaco-
dynamics of the drug) [5]. The NEISS-AIP paper found
that individuals over 65 years of age accounted for 50% of
all hospitalisations for an adverse drug reactions [12],
which is comparable to our figure of 65% for people over
60 (21% of the UK population).
The largest burden of ADRs in the 0–14 year age group
(44%) was with systemic agents. Approximately 42% of
paediatric prescriptions are 'off-label' (drug use outside its
licence) and these are more likely to cause ADRs [19]. It
should be possible to examine if the availability of new
prescribing guidelines following the publication of the
specific British National Formulary for Children in 2005
has had an effect on ADRs and off label drug use in this
cohort.
Sex
Pirmohamed et al. reported that 59% the patients admit-
ted with an adverse drug reaction were female. Our data
provides further support to this. Further research to eluci-
date whether this relationship occurs because women are
more likely to develop adverse drug reactions or because
women are more likely to report adverse drug reactions is
needed. It is widely known that women tend to present
more to their doctors for treatment and consequently
would be expected to experience more ADRs, however,
our data showed that for non-ADR causes women had a
similar number of hospital episodes as men. Rademaker
has suggested that pharmacological, immunological and
hormonal differences and the fact that women take more
medications may explain some gender differences [20].
Major drug groups
Systemic agents (Y43), which includes cancer chemother-
apy, were the most common cause of admissions in our
study, similar to the findings of Waller and colleagues
[11]. This will require further attention as estimates of the
life time risk of cancer are reported to be 1 in 3 [21].
Increase in ADRs may also be due to more aggressive man-
agement made permissible by bone marrow rescue with
growth colony stimulating factors (neutropenia is a com-
mon serious side effect of chemotherapy). The only other
comparable study to ours in terms of size and generalisa-
bility is the US NEISS-AIP [13]. Even though their thera-
peutic drug categories are different to ours, their top five
classes included (in brackets are approximately equivalent
ICD-10 codes): central nervous system agents (Y45–50),
antimicrobial agents (Y40–1), hormone modifying agents
(Y42), haematological and oncology agents (Y43–4) and
cardiovascular agents (Y52), which is broadly similar to
findings using HES data for England.
Implications for policy & conclusions
Adverse drug reactions have major clinical, public health
and economic implications but our data suggest that
admissions associated with adverse drug reactions are not
being well recorded by NHS hospitals in England. A key
requirement would be to include more detailed break-
down of drugs implicated in ADRs. Several European
countries also include causality assessment criteria by
which likelihood of ADR being related to a particular drug
can be estimated. Other suggestions include linking these
episodes to prescribing in primary care or pharmacies.
The current deficiencies in routine systems for monitoring
ADRs have several important implications. Firstly, the
NHS is not able to monitor accurately the burden of ill-
health and mortality, or the financial costs, of adverse
drug reactions. Secondly, potentially valuable informa-
tion that could help us understand the aetiology of
adverse drug reactions and identify patients for further
studies (for example pharmacogenetic studies), is not
being recorded. Finally, if accurate information on admis-
sions due to adverse drug reactions is not available, then
the NHS can not assess the impact of interventions to
improve prescribing. There is strong support for such
interventions but if they are introduced, without accurate
routine information on the burden of adverse drug reac-
tions, we have no way of measuring their clinical and their
cost effectiveness.
Locally, we are developing educational interventions and
mechanisms to feedback information on rates of correct
medical prescribing, drug interactions and of recording of
adverse drug reactions to hospital doctors and clinical
coders in hospitals linked to Imperial College's School of
Medicine. We will be evaluating the impact of such inter-
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ventions on the recording of adverse drug reactions and
using the information generated to develop and monitor
the impact of preventive strategies to prevent such events.
Hospitals in other areas should also consider adopting
their own interventions to improve the identification and
coding of admissions linked to adverse drug reactions.
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